Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $52.95 USD
Change Today -0.55 / -1.03%
Volume 153.4K
INSY On Other Exchanges
As of 11:53 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

insys therapeutics inc (INSY) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/24/15 - $67.87
52 Week Low
05/15/14 - $20.52
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

insys therapeutics inc (INSY) Related Businessweek News

No Related Businessweek News Found

insys therapeutics inc (INSY) Details

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients; and Dronabinol SG Capsule, a dronabinol soft gelatin capsule that is generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. Its products candidates also include Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol. The company is headquartered in Chandler, Arizona.

382 Employees
Last Reported Date: 03/3/15

insys therapeutics inc (INSY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $889.2K
Chief Financial Officer
Total Annual Compensation: $383.0K
General Counsel and Corporate Secretary
Total Annual Compensation: $315.5K
Compensation as of Fiscal Year 2014.

insys therapeutics inc (INSY) Key Developments

Insys Therapeutics, Inc. Commences Dosing in Phase 1/2 Safety and Pharmacokinetic Study of Cannabidiol Oral Solution in Pediatric Epilepsy Patients

Insys Therapeutics, Inc. announced that it has commenced dosing of pediatric epilepsy patients in a Phase 1/2 safety and harmacokinetic (PK) study in pediatric subjects with treatment-resistant seizures. The clinical trial will evaluate multiple ascending doses of Insys' pharmaceutical cannabidiol (CBD) oral solution at three different dosage strengths. The trial is being conducted at multiple study centers across the U.S. In addition to the ongoing Phase 1/2 study, the Company's CBD clinical development program includes Phase 3 clinical trials to evaluate the safety and efficacy of its CBD candidate for the treatment of Lennox-Gastaut syndrome and Dravet syndrome, two rare forms of pediatric epilepsy for which Insys' pharmaceutical CBD formulation has received orphan drug designation. The FDA granted Fast Track designation to Insys' pharmaceutical CBD formulation for the treatment of Dravet syndrome earlier 2015. The company expects that its new, DEA-inspected facility in Round Rock, Texas, will enable it to manufacture ample quantities of CBD for its research and commercial plans.

INSYS Therapeutics, Inc., Annual General Meeting, May 05, 2015

INSYS Therapeutics, Inc., Annual General Meeting, May 05, 2015., at 11:00 US Mountain Standard Time. Location: headquarters located at 1333 South Spectrum Blvd. Agenda: To elect the two Class II directors nominated by the Board; and to ratify the selection by audit committee of BDO USA, LLP as independent registered public accounting firm for the fiscal year ending December 31, 2015.

INSYS Therapeutics, Inc. Presents at 2015 Deutsche Bank Pharma OneonOne Day, Mar-26-2015

INSYS Therapeutics, Inc. Presents at 2015 Deutsche Bank Pharma OneonOne Day, Mar-26-2015 . Venue: JW Marriott Denver at Cherry Creek, 150 Clayton Lane, Denver, CO 80206, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INSY:US $52.95 USD -0.55

INSY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $8.84 USD -0.15
Array BioPharma Inc $6.81 USD +0.2401
BioDelivery Sciences International Inc $7.94 USD +0.04
Depomed Inc $23.69 USD +0.33
Spectrum Pharmaceuticals Inc $5.97 USD -0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation INSY Industry Range
Price/Earnings 52.9x
Price/Sales 8.6x
Price/Book 11.7x
Price/Cash Flow 51.4x
TEV/Sales 8.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSYS THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at